BR112016001461A2 - Método ou processo para modificar a fucosilação em um sistema de expressão de proteínas eucariótico e/ou eucariote, glicoproteína, e, uso de uma glicoproteína - Google Patents
Método ou processo para modificar a fucosilação em um sistema de expressão de proteínas eucariótico e/ou eucariote, glicoproteína, e, uso de uma glicoproteínaInfo
- Publication number
- BR112016001461A2 BR112016001461A2 BR112016001461A BR112016001461A BR112016001461A2 BR 112016001461 A2 BR112016001461 A2 BR 112016001461A2 BR 112016001461 A BR112016001461 A BR 112016001461A BR 112016001461 A BR112016001461 A BR 112016001461A BR 112016001461 A2 BR112016001461 A2 BR 112016001461A2
- Authority
- BR
- Brazil
- Prior art keywords
- glycoprotein
- eukaryotic
- fucosylation
- expression system
- protein expression
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 7
- 102000004169 proteins and genes Human genes 0.000 title abstract 6
- 108090000623 proteins and genes Proteins 0.000 title abstract 6
- 102000003886 Glycoproteins Human genes 0.000 title abstract 4
- 108090000288 Glycoproteins Proteins 0.000 title abstract 4
- 230000014509 gene expression Effects 0.000 title abstract 4
- 230000033581 fucosylation Effects 0.000 title abstract 3
- 241000206602 Eukaryota Species 0.000 title abstract 2
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 229910052748 manganese Inorganic materials 0.000 abstract 1
- 239000011572 manganese Substances 0.000 abstract 1
- 229910001437 manganese ion Inorganic materials 0.000 abstract 1
- 230000004481 post-translational protein modification Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/005—Glycopeptides, glycoproteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/54—F(ab')2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/72—Increased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- AIDS & HIV (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Saccharide Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN3262CH2013 | 2013-07-23 | ||
| IN3265CH2013 | 2013-07-23 | ||
| PCT/IB2014/063348 WO2015011660A1 (en) | 2013-07-23 | 2014-07-23 | Methods for controlling fucosylation levels in proteins |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112016001461A2 true BR112016001461A2 (pt) | 2017-08-29 |
Family
ID=52392808
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112016001461A BR112016001461A2 (pt) | 2013-07-23 | 2014-07-23 | Método ou processo para modificar a fucosilação em um sistema de expressão de proteínas eucariótico e/ou eucariote, glicoproteína, e, uso de uma glicoproteína |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US9856502B2 (enExample) |
| EP (2) | EP3024922A4 (enExample) |
| JP (1) | JP6480926B2 (enExample) |
| KR (1) | KR102062784B1 (enExample) |
| CN (1) | CN105392878A (enExample) |
| AU (1) | AU2014294618B2 (enExample) |
| BR (1) | BR112016001461A2 (enExample) |
| CA (1) | CA2926967C (enExample) |
| CU (1) | CU24312B1 (enExample) |
| EA (1) | EA201690269A1 (enExample) |
| HK (1) | HK1220228A1 (enExample) |
| MX (1) | MX2016001042A (enExample) |
| NZ (1) | NZ716182A (enExample) |
| PE (1) | PE20160218A1 (enExample) |
| PH (1) | PH12016500158A1 (enExample) |
| SG (1) | SG11201600067YA (enExample) |
| TW (1) | TWI621711B (enExample) |
| WO (1) | WO2015011660A1 (enExample) |
| ZA (1) | ZA201601113B (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8524233B2 (en) | 2008-03-14 | 2013-09-03 | Biocon Limited & Centro de Immunologia Molecular | Monoclonal antibody and a method thereof |
| KR102623965B1 (ko) | 2014-12-01 | 2024-01-11 | 암젠 인크 | 당단백질의 글리칸 함량 수준을 조작하는 방법 |
| ES2991182T3 (es) * | 2016-10-21 | 2024-12-02 | Biocon Ltd | Un anticuerpo monoclonal y un método de uso para el tratamiento del lupus |
| AU2017360807B2 (en) * | 2016-11-18 | 2024-11-28 | Biocon Limited | Rapid and efficient de-glycosylation of glycoproteins |
| EP3558363A1 (en) | 2016-12-21 | 2019-10-30 | Amgen Inc. | Anti-tnf alpha antibody formulations |
| CN111954719B (zh) | 2018-03-26 | 2025-07-18 | 美国安进公司 | 细胞培养物中产生的抗体的总去岩藻糖基化糖型 |
| KR102742590B1 (ko) * | 2018-04-20 | 2024-12-16 | (주)셀트리온 | 당단백질의 푸코실레이션을 조절하는 방법 |
| CN112752769B (zh) * | 2018-08-10 | 2024-12-10 | 豪夫迈·罗氏有限公司 | 用于调节蛋白糖基化的细胞培养策略 |
| HU231514B1 (hu) | 2018-11-07 | 2024-07-28 | Richter Gedeon Nyrt. | Sejttenyészetben előállított rekombináns glikoprotein glikozilációs mintázatának megváltoztatására szolgáló módszer |
| SG11202104092UA (en) * | 2018-11-13 | 2021-05-28 | Janssen Biotech Inc | Control of trace metals during production of anti-cd38 antibodies |
| JP7469593B2 (ja) * | 2018-12-27 | 2024-04-17 | 東ソー株式会社 | 抗体依存性細胞傷害活性が向上した抗体を製造する方法 |
| CN112779307B (zh) * | 2021-01-11 | 2022-04-19 | 苏州药明生物技术有限公司 | 一种两阶段调节cho表达外源蛋白糖型的方法 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| WO1990005144A1 (en) | 1988-11-11 | 1990-05-17 | Medical Research Council | Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| ES2176484T3 (es) | 1995-08-18 | 2002-12-01 | Morphosys Ag | Bancos de proteinas/(poli)peptidos. |
| WO1998043089A1 (en) * | 1997-03-03 | 1998-10-01 | Bristol-Myers Squibb Company | Monoclonal antibodies to human cd6 |
| WO2003073843A2 (en) | 2002-03-05 | 2003-09-12 | Artemis Pharmaceuticals Gmbh | Inbred embryonic stem-cell derived mice |
| AU2006255085A1 (en) | 2005-06-03 | 2006-12-14 | Genentech, Inc. | Method of producing antibodies with modified fucosylation level |
| WO2007070315A2 (en) | 2005-12-08 | 2007-06-21 | Amgen Inc. | Improved production of glycoproteins using manganese |
| US7846724B2 (en) * | 2006-04-11 | 2010-12-07 | Hoffmann-La Roche Inc. | Method for selecting CHO cell for production of glycosylated antibodies |
| US8524233B2 (en) * | 2008-03-14 | 2013-09-03 | Biocon Limited & Centro de Immunologia Molecular | Monoclonal antibody and a method thereof |
| WO2010141855A1 (en) | 2009-06-05 | 2010-12-09 | Momenta Pharmaceuticals, Inc. | Methods of modulating fucosylation of glycoproteins |
| BR112012025645A2 (pt) * | 2010-04-07 | 2017-12-12 | Momenta Pharmaceuticals Inc | glicanos de alta manose. |
| EP2809773B1 (en) * | 2012-01-30 | 2020-09-02 | Dr. Reddy's Laboratories Limited | Process of modulating man5 and/or afucosylation content of glycoprotein composition |
-
2014
- 2014-07-23 AU AU2014294618A patent/AU2014294618B2/en active Active
- 2014-07-23 NZ NZ716182A patent/NZ716182A/en unknown
- 2014-07-23 JP JP2016528640A patent/JP6480926B2/ja active Active
- 2014-07-23 BR BR112016001461A patent/BR112016001461A2/pt not_active IP Right Cessation
- 2014-07-23 EP EP14830053.6A patent/EP3024922A4/en not_active Ceased
- 2014-07-23 KR KR1020167004763A patent/KR102062784B1/ko active Active
- 2014-07-23 CA CA2926967A patent/CA2926967C/en active Active
- 2014-07-23 US US14/905,350 patent/US9856502B2/en active Active
- 2014-07-23 MX MX2016001042A patent/MX2016001042A/es unknown
- 2014-07-23 WO PCT/IB2014/063348 patent/WO2015011660A1/en not_active Ceased
- 2014-07-23 SG SG11201600067YA patent/SG11201600067YA/en unknown
- 2014-07-23 CU CUP2016000008A patent/CU24312B1/xx unknown
- 2014-07-23 PE PE2016000087A patent/PE20160218A1/es not_active Application Discontinuation
- 2014-07-23 EA EA201690269A patent/EA201690269A1/ru unknown
- 2014-07-23 HK HK16108338.6A patent/HK1220228A1/zh unknown
- 2014-07-23 CN CN201480041292.1A patent/CN105392878A/zh active Pending
- 2014-07-23 EP EP23196563.3A patent/EP4282975A3/en active Pending
- 2014-07-24 TW TW103125274A patent/TWI621711B/zh not_active IP Right Cessation
-
2016
- 2016-01-22 PH PH12016500158A patent/PH12016500158A1/en unknown
- 2016-02-18 ZA ZA2016/01113A patent/ZA201601113B/en unknown
-
2017
- 2017-11-21 US US15/819,351 patent/US10308970B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EA201690269A1 (ru) | 2016-05-31 |
| SG11201600067YA (en) | 2016-02-26 |
| AU2014294618B2 (en) | 2019-06-27 |
| CA2926967A1 (en) | 2015-01-29 |
| EP4282975A2 (en) | 2023-11-29 |
| KR102062784B1 (ko) | 2020-01-07 |
| CN105392878A (zh) | 2016-03-09 |
| EP3024922A1 (en) | 2016-06-01 |
| HK1220228A1 (zh) | 2017-04-28 |
| JP6480926B2 (ja) | 2019-03-13 |
| WO2015011660A1 (en) | 2015-01-29 |
| MX2016001042A (es) | 2017-01-05 |
| ZA201601113B (en) | 2017-08-30 |
| CU20160008A7 (es) | 2016-11-29 |
| NZ716182A (en) | 2018-07-27 |
| US20160138065A1 (en) | 2016-05-19 |
| CU24312B1 (es) | 2018-02-08 |
| KR20160036589A (ko) | 2016-04-04 |
| EP3024922A4 (en) | 2017-03-29 |
| PE20160218A1 (es) | 2016-05-09 |
| US9856502B2 (en) | 2018-01-02 |
| JP2016525352A (ja) | 2016-08-25 |
| TWI621711B (zh) | 2018-04-21 |
| AU2014294618A1 (en) | 2016-02-11 |
| US10308970B2 (en) | 2019-06-04 |
| TW201512396A (zh) | 2015-04-01 |
| EP4282975A3 (en) | 2024-02-28 |
| CA2926967C (en) | 2020-12-08 |
| PH12016500158A1 (en) | 2016-04-25 |
| US20180087080A1 (en) | 2018-03-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112016001461A2 (pt) | Método ou processo para modificar a fucosilação em um sistema de expressão de proteínas eucariótico e/ou eucariote, glicoproteína, e, uso de uma glicoproteína | |
| BR112015004467A2 (pt) | método para controlar a heterogeneidade de proteínas | |
| BR112013027228A2 (pt) | método para manipular o controle remoto de um sistema de elevador, e, sistema de elevador | |
| GB2522534B (en) | Control system and method for improving turning performance by braking | |
| BR112014009982A2 (pt) | sistema integrado e método para intensificar o desempenho de operações subterrânes, e, sistema de controle de operação subterrânea | |
| EP3011730A4 (en) | Systems and methods for enhancement of facial expressions | |
| BR112014029884A2 (pt) | sistemas de controle e método. | |
| BR112013032215A2 (pt) | método e sistema para processamento de consultas de saldo de contas financeiras | |
| AR096869A1 (es) | Neurotoxinas catiónicas | |
| EP3230853A4 (en) | SYSTEM AND METHOD FOR PERFORMING A COMPILED APPLICATION CODE ACCORDING TO TWO ARCHITECTURES OF INSTRUCTION GAMES | |
| GB2537077A (en) | Methods for sequencing nucleic acids | |
| BR112014009538A2 (pt) | publicação atrasada em sistemas de controle de processo | |
| EP3090063A4 (en) | System and method for detection of rna species | |
| EP3046092A4 (en) | Landing decision assistance system, landing decision assistance method, and landing decision assistance program | |
| EP3067367A4 (en) | Method for purifying recombinant protein | |
| WO2014197885A3 (en) | Inhibitors of complement factor h | |
| MX2018001536A (es) | Metodo para la reduccion de proteinas de celulas hospederas en cromatografia de afinidad. | |
| BR112013024105A2 (pt) | controlador luminoso, sistema de iluminação e método para o controle de um sistema de iluminação usando um controlador luminoso | |
| EP3088411A4 (en) | Method for purifying antibody having low isoelectric point | |
| MX2015014424A (es) | Construcciones de proteinas mitocondriales y sus usos. | |
| WO2014018785A3 (en) | Biorefinery control system, components therefor, and methods of use | |
| EP3268389A4 (en) | Method of purifying albumin-fusion proteins | |
| EP3013960A4 (en) | Modified matrix proteins of vesicular stomatitis virus | |
| BR112013026610A2 (pt) | sistema de controle de processo de monitoramento | |
| MY171938A (en) | Proteins specific for baff and b7rp1 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
| B04C | Request for examination: application reinstated [chapter 4.3 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 5A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2524 DE 21-05-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |